US equities
|
MU
$928.76
▲+0.00%
SNDK
$1,304.84
▲+0.00%
SKHY
$145.36
▲+0.00%
TSLA
$407.46
▲+0.00%
NVDA
$217.94
▲+0.00%
INTC
$93.74
▲+0.00%
SPCX
$148.58
▲+0.00%
STX
$667.85
▲+0.00%
MU
$928.76
▲+0.00%
SNDK
$1,304.84
▲+0.00%
SKHY
$145.36
▲+0.00%
TSLA
$407.46
▲+0.00%
NVDA
$217.94
▲+0.00%
INTC
$93.74
▲+0.00%
SPCX
$148.58
▲+0.00%
STX
$667.85
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by AXIM BIOTECHNOLOGIES, INC
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
December 13, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
Tickers
AXIM
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions
December 06, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
Tickers
AXIM
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
October 04, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
Tickers
AXIM
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022
September 29, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
Tickers
AXIM
AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season
July 26, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
Tickers
AXIM